Home
>
US Stocks
>
Hexo Corp

Hexo Corp (HEXO)

$1

+0.02

(+2.04%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Hexo Corp

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 52.76M → 24.16M (in $), with an average decrease of 17.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -710.88M → 722.0K (in $), with an average increase of 2101.2% per quarter

  • Vs ZTS

    In the last 1 year, Zoetis Inc - Class A has given 1.7% return, outperforming this stock by 73.3%

  • Vs ZTS

    In the last 3 years, Zoetis Inc - Class A has given 22.3% return, outperforming this stock by 119.9%

Performance

  • $0.99
    $1.04
    $1.00
    downward going graph

    0.99%

    Downside

    Day's Volatility :4.46%

    Upside

    3.5%

    downward going graph
  • $0.90
    $3.99
    $1.00
    downward going graph

    9.94%

    Downside

    52 Weeks Volatility :77.43%

    Upside

    74.94%

    downward going graph

Returns

Period Hexo CorpRussel 2000Index (Russel 2000)
3 Months
-38.27%
-8.3%
-8.3%
6 Months
-60.25%
-6.5%
-6.5%
1 Year
-71.71%
-6.1%
-6.1%
3 Years
-97.55%
21.8%
21.8%

Highlights

Market Capitalization
43.1M
Book Value
$5.88
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.65
Wall Street Target Price
1.26
Profit Margin
-203.25%
Operating Margin TTM
-115.33%
Return On Assets TTM
-14.22%
Return On Equity TTM
-83.49%
Revenue TTM
148.1M
Revenue Per Share TTM
3.86
Quarterly Revenue Growth YOY
-54.2%
Gross Profit TTM
-75.7M
EBITDA
-142.7M
Diluted Eps TTM
-1.65
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.32
EPS Estimate Next Year
-0.51
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 12 Wall street analysts offering stock ratings for Hexo Corp(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
6
7
8
Sell
6
7
7

Analyst Forecast

What analysts predicted

Upside of 26.0%

Current $1.00
Target $1.26

Company Financials

FY17Y/Y Change
Revenue
4.1M
-
Net Income
-12.4M
↑ 15808.34%
Net Profit Margin
-303.1%
-
FY18Y/Y Change
Revenue
4.9M
↑ 20.43%
Net Income
-23.3M
↑ 88.04%
Net Profit Margin
-473.25%
↓ 170.15%
FY19Y/Y Change
Revenue
47.5M
↑ 863.55%
Net Income
-81.6M
↑ 249.31%
Net Profit Margin
-171.57%
↑ 301.68%
FY20Y/Y Change
Revenue
80.8M
↑ 69.92%
Net Income
-546.5M
↑ 570.01%
Net Profit Margin
-676.48%
↓ 504.91%
FY21Y/Y Change
Revenue
123.8M
↑ 53.21%
Net Income
-114.8M
↓ 79.0%
Net Profit Margin
-92.72%
↑ 583.76%
FY22Y/Y Change
Revenue
149.3M
↑ 54.4%
Net Income
-838.9M
↑ 835.51%
Net Profit Margin
-561.8%
↓ 469.08%
Q4 FY21Q/Q Change
Revenue
40.5M
↑ 29.48%
Net Income
-94.7M
↑ 69.92%
Net Profit Margin
-233.67%
↓ 55.62%
Q1 FY22Q/Q Change
Revenue
41.4M
↑ 5.13%
Net Income
-557.2M
↑ 506.19%
Net Profit Margin
-1.3K%
↓ 1113.65%
Q2 FY22Q/Q Change
Revenue
35.4M
↓ 13.63%
Net Income
-112.8M
↓ 79.6%
Net Profit Margin
-318.21%
↑ 1029.11%
Q3 FY22Q/Q Change
Revenue
33.3M
↓ 6.55%
Net Income
-78.5M
↓ 30.73%
Net Profit Margin
-235.86%
↑ 82.35%
Q4 FY22Q/Q Change
Revenue
26.3M
↓ 16.0%
Net Income
-41.3M
↓ 43.99%
Net Profit Margin
-157.26%
↑ 78.6%
Q1 FY23Q/Q Change
Revenue
18.1M
↓ 32.46%
Net Income
539.5K
↓ 101.28%
Net Profit Margin
2.99%
↑ 160.25%
FY17Y/Y Change
Total Assets
56.2M
↑ 6820.5%
Total Liabilities
23.7M
↑ 205293.96%
FY18Y/Y Change
Total Assets
335.0M
↑ 496.3%
Total Liabilities
12.1M
↓ 48.93%
FY19Y/Y Change
Total Assets
881.0M
↑ 163.0%
Total Liabilities
104.3M
↑ 760.11%
FY20Y/Y Change
Total Assets
693.0M
↓ 21.35%
Total Liabilities
136.2M
↑ 30.6%
FY21Y/Y Change
Total Assets
1.3B
↑ 89.3%
Total Liabilities
579.5M
↑ 325.53%
FY22Y/Y Change
Total Assets
532.1M
↓ 48.09%
Total Liabilities
287.0M
↓ 36.63%
Q4 FY21Q/Q Change
Total Assets
1.3B
↑ 23.04%
Total Liabilities
444.2M
↓ 5.13%
Q1 FY22Q/Q Change
Total Assets
763.4M
↓ 39.65%
Total Liabilities
398.2M
↓ 7.59%
Q2 FY22Q/Q Change
Total Assets
660.3M
↓ 12.83%
Total Liabilities
371.9M
↓ 5.89%
Q3 FY22Q/Q Change
Total Assets
532.1M
↓ 19.79%
Total Liabilities
287.0M
↓ 23.19%
Q4 FY22Q/Q Change
Total Assets
453.4M
↓ 9.4%
Total Liabilities
259.5M
↓ 3.85%
Q1 FY23Q/Q Change
Total Assets
394.3M
↓ 14.45%
Total Liabilities
203.7M
↓ 22.78%
FY17Y/Y Change
Operating Cash Flow
-5.3M
↑ 4591.41%
Investing Cash Flow
-6.3M
-
Financing Cash Flow
48.2M
-
FY18Y/Y Change
Operating Cash Flow
-22.2M
↑ 317.71%
Investing Cash Flow
-200.4M
↑ 3060.93%
Financing Cash Flow
283.2M
↑ 487.8%
FY19Y/Y Change
Operating Cash Flow
-128.4M
↑ 478.94%
Investing Cash Flow
-7.6M
↓ 96.18%
Financing Cash Flow
150.6M
↓ 46.81%
FY20Y/Y Change
Operating Cash Flow
-94.6M
↓ 26.38%
Investing Cash Flow
-83.0M
↑ 986.25%
Financing Cash Flow
248.2M
↑ 64.8%
FY21Y/Y Change
Operating Cash Flow
-43.1M
↓ 54.45%
Investing Cash Flow
-451.6M
↑ 443.83%
Financing Cash Flow
378.0M
↑ 52.28%
FY22Y/Y Change
Operating Cash Flow
-91.2M
↑ 170.93%
Investing Cash Flow
-12.8M
↓ 96.39%
Financing Cash Flow
116.3M
↓ 60.64%
Q4 FY21Q/Q Change
Operating Cash Flow
-45.6M
↑ 115.39%
Investing Cash Flow
-96.1M
↓ 69.91%
Financing Cash Flow
132.3M
↓ 59.86%
Q1 FY22Q/Q Change
Operating Cash Flow
-27.6M
↓ 37.61%
Investing Cash Flow
6.1M
↓ 106.55%
Financing Cash Flow
7.4M
↓ 94.25%
Q2 FY22Q/Q Change
Operating Cash Flow
-7.3M
↓ 73.49%
Investing Cash Flow
-10.7M
↓ 276.19%
Financing Cash Flow
-332.1K
↓ 104.53%
Q3 FY22Q/Q Change
Operating Cash Flow
-12.2M
↑ 66.84%
Investing Cash Flow
84.9M
↓ 891.04%
Financing Cash Flow
-18.8M
↑ 5524.12%

Technicals Summary

Sell

Neutral

Buy

Hexo Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Hexo Corp
Hexo Corp
-23.66%
-60.25%
-71.71%
-97.55%
-99.66%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-3.67%
-25.55%
-1.95%
-23.14%
-8.16%
Zoetis Inc.
Zoetis Inc.
-3.69%
10.65%
0.51%
22.32%
101.29%
Viatris Inc.
Viatris Inc.
3.44%
-14.56%
-20.73%
-42.9%
-42.9%
Catalent, Inc.
Catalent, Inc.
-23.38%
-25.7%
-66.09%
-50.96%
-4.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Hexo Corp
Hexo Corp
NA
NA
NA
-0.32
-0.83
-0.14
0.0
5.88
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
144.75
144.75
1.87
2.1
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
36.8
36.8
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.88
5.88
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.06
16.06
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Hexo Corp
Hexo Corp
Sell
$43.1M
-99.66%
NA
-203.25%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$8.9B
-8.16%
144.75
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$75.3B
101.29%
36.8
25.59%
Viatris Inc.
Viatris Inc.
Hold
$11.1B
-42.9%
5.88
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.7B
-4.0%
16.06
8.62%

Institutional Holdings

  • Mirae Asset Global Investments (Korea) Co Ltd

    2.80%

  • Renaissance Technologies Corp

    0.78%

  • Millennium Management LLC

    0.33%

  • Scotia Capital Inc

    0.22%

  • Susquehanna International Group, LLP

    0.21%

  • JANE STREET GROUP, LLC

    0.18%

Corporate Announcements

  • Hexo Corp Earnings

    Hexo Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

HEXO Corp is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. The Company serves the Canadian adult-use markets under its HEXO Cannabis, Up Cannabis and Original Stash brands, and the medical market under HEXO medical cannabis.

Organization
Hexo Corp
Employees
0
CEO
Mr. Mark Attanasio
Industry
Pharmaceuticals: Other

Discover More

FAQs